Targeting an energy sensor to prevent energy excess in the liver
- PMID: 34560016
 - DOI: 10.1016/S2468-1253(21)00307-1
 
Targeting an energy sensor to prevent energy excess in the liver
Conflict of interest statement
GL-HW has served as an advisory committee member for Gilead Sciences, and as a speaker for Abbott, AbbVie, Bristol Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche. VW-SW has served as an advisory committee member for AbbVie, Allergan, Echosens, Gilead Sciences, Janssen, Perspectum Diagnostics, Pfizer, and Terns, and a speaker for Bristol Myers Squibb, Echosens, Gilead Sciences, and Merck.
Comment on
- 
  
  Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.
 
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
